molnupiravir
Article
molnupiravir is a recurring brand in the Astral Codex Ten archive, appearing 2 times across 2 issues between December 22, 2021 and December 22, 2021. The archive places it in contexts such as “evidence for molnupiravir is in many ways weaker than fluvoxamine”; “communications about Merck’s drug molnupiravir”. It most often appears alongside budesonide, FDA, fluvoxamine.
Metadata
- Category: Brands
- Mention count: 2
- Issue count: 2
- First seen: December 22, 2021
- Last seen: December 22, 2021
Appears In
- The FDA Has Punted Decisions About Luvox Prescription To The Deepest Recesses Of The Human Soul
- Addendum To Luvox Post
Related Pages
-
- budesonide (2 shared issues)
-
- FDA (2 shared issues)
-
- fluvoxamine (2 shared issues)
-
- Luvox (2 shared issues)
-
- Merck (2 shared issues)
-
- Vox (2 shared issues)
-
- aspirin (1 shared issues)
-
- Astralcodexten Com (1 shared issues)
-
- Congo (1 shared issues)
-
- COVID (1 shared issues)
-
- CS Lewis (1 shared issues)
-
- Dr. Ed Mills (1 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
But according to Kelsey Piper at Vox, that’s where they are right now:
Inline links: according to Kelsey Piper at Vox
[Professor Ed] Mills, who thinks that fluvoxamine and budesonide are both appropriate to prescribe to patients sick with Covid-19, compares public messaging on fluvoxamine to communications about Merck’s drug molnupiravir. The evidence for molnupiravir is in many ways weaker than the evidence for fluvoxamine, but molnupiravir was produced by a major pharmaceutical company that can shepherd it through the process of becoming a recommended drug. On a call last week, Mills said, the FDA told him “they don’t know how to deal with submissions where there isn’t someone to be responsible for it.”
In my post yesterday, I quoted a Vox article describing work by Dr. Ed Mills and others to get the FDA to approve Luvox for COVID. As of that point, the FDA didn’t know how to process an application without a sponsoring drug company:
Inline links: quoted a Vox
[Professor Ed] Mills, who thinks that fluvoxamine and budesonide are both appropriate to prescribe to patients sick with Covid-19, compares public messaging on fluvoxamine to communications about Merck’s drug molnupiravir. The evidence for molnupiravir is in many ways weaker than the evidence for fluvoxamine, but molnupiravir was produced by a major pharmaceutical company that can shepherd it through the process of becoming a recommended drug. On a call last week, Mills said, the FDA told him “they don’t know how to deal with submissions where there isn’t someone to be responsible for it.”